This study is evaluating the effectiveness of a procedure called irreversible electroporation, which uses electrical pulses to destroy cancer cells, in people with stage III pancreatic cancer who have received 3 months of chemotherapy.
This trial is treating patients with unresectable, stage III pancreatic cancer.
This is a surgical trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy (DIRECT/InspIRE Australia)
Other Non-Commercial Sponsor
Walter and Eliza Hall Institute
This is an open-label, prospective, multi-centre registry-based study evaluating the use of Irreversible Electroporation (IRE) with the NanoKnife system in unresectable stage 3 pancreatic cancer. Irreversible electroporation (IRE) is a technique using non-thermal energy to create permanent nanopores in the cell membrane in order to disrupt cellular homeostasis. After delivering a sufficient number of high voltage pulses, the cells within the electrical field will be irreversibly damaged. Eligible participants must have received 3 months of FOLFIRINOX or gemcitabine-based chemotherapy prior to enrolment. All participants will undergo IRE with the NanoKnife System, and the IRE procedure should be undertaken 1-3 weeks from the completion of 3 months of chemotherapy. Only a surgeon qualified in the use of the NanoKnife System will perform the procedure, and the procedure takes around 2-3 hours.
Recruiting Hospitals Read More